Essential Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

Essential Partners’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-930	Closed	-$4.19K	–	2800
2025 Q2	$4.19K	Buy	+930	New	+$4.18K	﹤0.01%	1102

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Essential Partners's YMAB Position: Q3 2025 in Review

Essential Partners sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 930 shares — an estimated $4.19K sold.

Essential Partners first reported a position in YMAB in Q2 2025 and held it in 1 quarter. The position peaked at $4.19K in Q2 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Essential Partners reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 930 Y-mAbs Therapeutics shares in Q3 2025, an estimated $4.19K.
Essential Partners first reported a position in Y-mAbs Therapeutics in Q2 2025 and held it in 1 quarter.
Essential Partners's Y-mAbs Therapeutics position peaked at $4.19K in Q2 2025.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.